<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA: Endocrine Surgery- adrenal, thyroid, parathyroid, pancreas Topic Collection</title>
    <link>http://jama.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Mon, 17 Dec 2012 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 01 Jan 2013 00:46:28 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@jama.jamanetwork.com</managingEditor>
    <webMaster>webmaster@jama.jamanetwork.com</webMaster>
    <item>
      <title>Thyroxine Monotherapy After Thyroidectomy Coming Full Circle </title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=181472</link>
      <pubDate>Wed, 20 Feb 2008 00:00:00 GMT</pubDate>
      <author>Cooper DS. </author>
      <description />
      <prism:volume xmlns:prism="prism">299</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">817</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">819</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.299.7.817</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=181472</guid>
    </item>
    <item>
      <title>Triiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy</title>
      <link>http://jama.jamanetwork.com/article.aspx?articleID=181484</link>
      <pubDate>Wed, 20 Feb 2008 00:00:00 GMT</pubDate>
      <author>Jonklaas J, Davidson B, Bhagat S, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Context&lt;/div&gt;Thyroidal production of triiodothyronine (T&lt;sub&gt;3&lt;/sub&gt;) is absent in athyreotic patients, leading to the suggestion that T&lt;sub&gt;3&lt;/sub&gt; deficiency may be unavoidable during levothyroxine (LT&lt;sub&gt;4&lt;/sub&gt;) therapy. However, trials evaluating therapy with combined LT&lt;sub&gt;4&lt;/sub&gt; and T&lt;sub&gt;3&lt;/sub&gt; have failed to demonstrate any consistent advantage of combination therapy.&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To determine whether T&lt;sub&gt;3&lt;/sub&gt; levels in patients treated with LT&lt;sub&gt;4&lt;/sub&gt; therapy were truly lower than in the same patients with native thyroid function.&lt;div class="boxTitle"&gt;Design, Setting, and Patients&lt;/div&gt;A prospective study conducted in the General Clinical Research Center, Georgetown University Medical Center, Washington, DC, between January 30, 2004, and June 20, 2007, of 50 euthyroid study participants aged 18 to 65 years who were scheduled for total thyroidectomy for goiter, benign nodular disease, suspected thyroid cancer, or known thyroid cancer. Following thyroidectomy, patients were prescribed LT&lt;sub&gt;4&lt;/sub&gt;. Patients with benign thyroid disease and thyroid cancer were treated to achieve a normal and suppressed serum thyroid-stimulating hormone (TSH) level, respectively. The LT&lt;sub&gt;4&lt;/sub&gt; dose was adjusted as necessary postoperatively to achieve the desired TSH goal.&lt;div class="boxTitle"&gt;Main Outcome Measure&lt;/div&gt;Thyroxine (tetraiodothyronine [T&lt;sub&gt;4&lt;/sub&gt;]), T&lt;sub&gt;3&lt;/sub&gt;, and TSH levels were measured twice preoperatively and twice postoperatively.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;By the end of the study, there were no significant decreases in T&lt;sub&gt;3&lt;/sub&gt; concentrations in patients receiving LT&lt;sub&gt;4&lt;/sub&gt; therapy compared with their prethyroidectomy T&lt;sub&gt;3&lt;/sub&gt; levels (mean, 127.2 ng/dL; 95% confidence interval [CI], 119.5-134.9 ng/dL vs 129.3 ng/dL; 95% CI, 121.9-136.7 ng/dL; P = .64). However, free T&lt;sub&gt;4&lt;/sub&gt; concentrations were significantly higher in patients treated with LT&lt;sub&gt;4&lt;/sub&gt; therapy (mean, 1.41 ng/dL; 95% CI, 1.33-1.49 ng/dL) compared with their native free T&lt;sub&gt;4&lt;/sub&gt; levels (1.05 ng/dL; 95% CI, 1.00-1.10 ng/dL; P &lt; .001). Serum TSH values of 4.5
mIU/L or less were achieved in 94% of patients by the end of the study.
The T&lt;sub&gt;3&lt;/sub&gt; concentrations were lower in the subgroup of patients whose therapy had not resulted in a TSH level of 4.5 mIU/L or less (P &lt; .001).&lt;div class="boxTitle"&gt;Conclusion&lt;/div&gt;In our study, normal T&lt;sub&gt;3&lt;/sub&gt; levels were achieved with traditional LT&lt;sub&gt;4&lt;/sub&gt; therapy alone in patients who had undergone near-total or total thyroidectomy, which suggests that T&lt;sub&gt;3&lt;/sub&gt; administration is not necessary to maintain serum T&lt;sub&gt;3&lt;/sub&gt; values at their endogenous prethyroidectomy levels.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">299</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">769</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">777</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.299.7.769</prism:doi>
      <guid>http://jama.jamanetwork.com/article.aspx?articleID=181484</guid>
    </item>
  </channel>
</rss>